Biofil Chemicals and Pharmaceuticals Limited - Balance (Quarterly)

Biofil Chemicals and Pharmaceuticals Limited
IN ˙ NSEI
34,74 ₹ ↑0,33 (0,96%)
2026-06-03
DEL PRIS
Balance (Quarterly)

Biofil Chemicals and Pharmaceuticals Limited Balance viser kontosaldi for virksomheden på tidspunkter. Balancedata inkluderer aktiver, omsætningsaktiver, anlægsaktiver, materielle anlægsaktiver (PPE), inventar, immaterielle aktiver, passiver, kortfristede forpligtelser, gæld, kapitalleasingforpligtelser, almindelige aktier, overført overskud, egne aktier og egenkapital.

Alle tal er gange 1,000,000.00 undtagen pr. andel enheder.

2021
09-30
2022
03-31
2022
09-30
2023
03-31
2023
09-30
2024
03-31
2024
09-30
2025
03-31
2025
09-30
2026
03-31
Kontanter 1 1 2 0 1 23 2 3 4 33
Ændring (%) -1,43 11,18 -76,66 52,93 3.871,30 -90,36 15,94 40,78 825,54
Aktiver Nuværende 281 93 239 224 334 384 336 426 484 359
Ændring (%) -66,82 156,69 -6,49 49,55 14,89 -12,48 26,60 13,78 -25,93
Aktiver 377 187 331 314 422 471 420 510 554 428
Ændring (%) -50,29 76,82 -5,18 34,42 11,53 -10,71 21,22 8,64 -22,61
Forpligtelser 212 19 160 141 245 289 236 322 341 213
Ændring (%) -91,05 746,23 -12,03 74,03 17,66 -18,13 36,10 5,84 -37,51
Egenkapital 165 168 171 173 177 182 184 188 213 216
Ændring (%) 1,95 1,50 1,24 2,13 3,01 1,06 2,09 13,43 1,22
Passiver og Aktiekapital 377 187 331 314 422 471 420 510 554 428
Ændring (%) -50,29 76,82 -5,18 34,42 11,53 -10,71 21,22 8,64 -22,61

Source: Capital IQ

How Much do you Like Fintel?
Please share your opinion of our service!
Excellent Bad
Other Listings
IN:524396 34,74 ₹
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista